NL-OMON40963CompletedNot Applicable
Trough level related side-effects of adalimumab therapy in patients with inflammatory bowel disease in clinical and biochemical remission, a cross-sectional cohort study - STADA: Side effects Trough level ADA
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •IBD diagnose, in clinical and biochemical remission on adalimumab maintenance therapy
Exclusion Criteria
- •-biochemical parameters contradicting complete remission. (high fecal calprotectin and CRP)
- •-conditions or co-morbidities which could potentially cause symptoms like, fatigue, joint pain and skin lesions (such as infectious disease, arthritis, malignancy or pregnancy).
- •-detectable anti-bodies to adalimumab,
Investigators
Similar Trials
Recruiting
Phase 3
Adalimumab effect on COVID-19IRCT20171105037262N4Bagheiat-allah University of Medical Sciences100
Completed
Not Applicable
Prospective study on the effects of adalimumab treatment in patients with rheumatoid arthritisMusculoskeletal DiseasesArthropathiesRheumatoid arthritisISRCTN68762628Academic Medical Center (AMC) (The Netherlands)50
Not yet recruiting
Phase 2
The effect of Adalimumab in the treatment of patients with chronic schizophreniaSchizophrenia.SchizophreniaIRCT20090117001556N126Tehran University of Medical Sciences50
Recruiting
Phase 4
Prospective follow-up study of adalimumab treatment in ankylosing spondylitis: efficacy with focus on uveitisAnkylosing spondylitisBechterew's disease10023213NL-OMON30515Vrije Universiteit Medisch Centrum100
Completed
Phase 3
Therapeutic Effects of Adalimumab in Patients with Resistant PsoriasisIRCT20120524009844N8Tabriz University of Medical Sciences60